Evotec SE: insider trades · Germany · BaFin

About Evotec SE

Evotec SE is a German life-science company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany under ticker EVT.DE. Founded in Hamburg in 1993, it has evolved into an internationally recognized partner in drug discovery and preclinical development, with a broad scientific and industrial footprint across Europe and the United States. The company remains headquartered in Hamburg, where its flagship research campus, the Manfred Eigen Campus, hosts major capabilities in high-throughput screening, neuroscience, iPSC-based platforms, and broad biology expertise. Evotec’s business model is built around two complementary pillars. The first, Discovery & Preclinical Development, spans target identification and validation, medicinal chemistry, in vitro and in vivo biology, biophysics, biomarkers, structural biology, pharmacology, and early safety assessment. The second, Just – Evotec Biologics, focuses on biologics development and manufacturing, leveraging AI/ML-enabled workflows, cell-line engineering, continuous manufacturing, and integrated CMC capabilities. The group also offers specialized services such as Cyprotex for ADME-Tox and multi-omics-based precision medicine tools. From a competitive standpoint, Evotec is positioned as a technology-rich integrated services provider rather than a traditional drug manufacturer. Its appeal lies in proprietary platforms, scientific depth, and the ability to support biotech companies, large pharmaceutical groups, academic institutions, and selected public-sector customers across the early drug-development value chain. The company’s geographic presence is substantial, with sites in Germany, the UK, France, Italy, and the US. Key locations include Hamburg, Göttingen, Munich, Abingdon, Toulouse, Lyon, Verona, Modena, Princeton, Seattle, and Redmond. Recent developments highlight a company in active transformation. In 2024, Evotec initiated a strategic reset toward profitable growth, smaller operational scale, and stronger cost discipline. During 2025 and into early 2026, management advanced the Horizon program, aimed at simplifying the global footprint, strengthening centers of excellence, and delivering structural cost savings. Full-year 2025 results released in April 2026 indicated solid execution in a still challenging environment, while first-quarter 2026 trading continued to reflect the ongoing transformation. For investors, Evotec remains a hybrid healthcare/biopharma name with meaningful exposure to innovation, partnering activity, and execution risk inherent in platform-based R&D services.